Publication Name	World Journal of Diabetes
Manuscript ID	99496
Country	United Kingdom

Received	2024-07-31 01:56
Peer-Review Started	2024-07-23 18:05
To Make the First Decision
Return for Revision	2024-10-10 08:16
Revised	2024-10-11 05:33
Second Decision	2024-11-04 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-04 08:17
Articles in Press	2024-11-04 08:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-12 01:40
Publish the Manuscript Online	2024-11-30 03:48

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Current perspectives and the future of disease-modifying therapies in type 1 diabetes
Manuscript Source	Invited Manuscript
All Author List	Sunetra Mondal and Joseph M Pappachan
ORCID	Author(s) ORCID Number Sunetra Mondal http://orcid.org/0000-0003-3064-466X Joseph M Pappachan http://orcid.org/0000-0003-0886-5255
Funding Agency and Grant Number
Corresponding Author	Joseph M Pappachan, MD, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Key Words	Teplizumab; Type 1 diabetes mellitus; Disease modifying therapy; β-cell function; C-peptide; Immunotherapy
Core Tip	Teplizumab is an anti-CD3 immunomodulator that can render the T cell anergic to its target antigen and thus protect against autoimmune beta cell destruction. It is approved for use in individuals aged above 8 years in early pre-clinical stages of type 1 diabetes mellitus to prevent progression to clinical stage (stage 3). C-peptide decline is halted and the need for insulin therapy can be delayed even after discontinuation of this therapeutic molecule. Adverse effects are mostly mild. The high cost and lack of availability limit its applicability in low- and middle-income countries.
Publish Date	2024-11-30 03:48
Citation	<p>Mondal S, Pappachan JM. Current perspectives and the future of disease-modifying therapies in type 1 diabetes. <i>World J Diabetes</i> 2025; 16(1): 99496</p>
URL	https://www.wjgnet.com/1948-9358/full/v16/i1/99496.htm
DOI	https://dx.doi.org/10.4239/wjd.v16.i1.99496

Full Article (PDF)	WJD-16-99496-with-cover.pdf
Manuscript File	99496_Auto_Edited_015733.docx
Answering Reviewers	99496-answering-reviewers.pdf
Audio Core Tip	99496-audio.m4a
Conflict-of-Interest Disclosure Form	99496-conflict-of-interest-statement.pdf
Copyright License Agreement	99496-copyright-assignment.pdf
Supplementary Material	99496-supplementary-material.pdf
Peer-review Report	99496-peer-reviews.pdf
Scientific Misconduct Check	99496-scientific-misconduct-check.png
Scientific Editor Work List	99496-scientific-editor-work-list.pdf
CrossCheck Report	99496-crosscheck-report.pdf